Broadcast Date: October 25th, 2016
Time: 10:00 am ET, 7:00 am PT
Label-free technologies provide critical information for the drug discovery process—from the screening of specific drug target binding interactions, to measuring the affinity of that binding. When used with purified proteins or membrane fractions, these assays are limited in providing rich insight into the complex milieu of cellular response signaling molecules. Bio-Layer Interferometry (BLI) has recently been demonstrated to monitor binding interactions in real-time with live cells, creating a novel cell-based BLI, or cBLI, that has the potential to increase the versatility of label-free assays in screening labs for finding “hits” that rely on more complex signal transduction.
Join us for this GEN webinar, which will describe the development of a cBLI assay on the Pall-ForteBio Octet HTX system and explore how high-throughput label-free assays can streamline the drug discovery process.
Who Should Attend
- Bioanalytical scientists
- Drug discovery and development scientists
- Signal transduction researchers
- Investigators concerned with bimolecular interactions
You Will Learn
- About a new cell-based, label-free method for monitoring signal transduction
- How cBLI can be applied to your drug discovery and development process, as well as streamline your research workflows
- Benefits of the Octet HTX system
Dennis Verzijl, Ph.D.
Director, Regional Marketing,
ForteBio – A Division of Pall Life Sciences